Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy
Authors:
- 1 August 2017
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (16) , 1621-1630
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJACC, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting StentsCirculation, 2012
- Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessationClinical Research in Cardiology, 2011
- Clopidogrel discontinuation and platelet reactivity following coronary stentingJournal of Thrombosis and Haemostasis, 2011
- The Platelet Activity After Clopidogrel Termination (PACT) StudyCirculation: Cardiovascular Interventions, 2010
- Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidencePharmacology & Therapeutics, 2009
- Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary SyndromeJAMA, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007